Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financi...( ovarian cancer non-Hodgkin's lymphoma a...)

Date:3/16/2009

, ovarian cancer, non-Hodgkin's lymphoma, and sarcoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling OPAXIO, pixantrone, and brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

                        Cell Therapeutics, Inc.

              Condensed Consolidated Statements of Operations
               (In thousands, except for per share amounts)
                                (unaudited)

                          Three Months          Year Ended
                           December 31,         December 31,
                          ------------         ------------
                           2008      2007       2008       2007
                           ----      ----       ----       ----
    Revenues:
      Product sales      $2,528       $47    $11,352        $47
      License and
       contract
       revenue               20        20         80         80
                             --        --         --         --
        Total revenues    2,548        67     11,432        127
  
'/>"/>
SOURCE  Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 
Related biology technology :

1. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
2. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
3. Cell Therapeutics, Inc. (CTI) BIO CEO Presentation to be Webcast
4. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
5. Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
6. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
8. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
9. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
10. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
11. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7